Cardiac angiogenesis and gene therapy: A strategy for myocardial revascularization

Current Opinion in Cardiology

Volumn 14, Issue 6, 1999, Pages 515-522

  Hamawy, Adam H ^a   Lee, Leonard Y ^a   Crystal, Ronald G ^a   Rosengart, Todd K ^b  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b EVANSTON HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; CORONARY ARTERY DISEASE; GENE THERAPY; GENETICS; HEART MUSCLE REVASCULARIZATION; HUMAN; METHODOLOGY; NEOVASCULARIZATION (PATHOLOGY); PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY;

ANIMALS; CORONARY DISEASE; GENE THERAPY; HUMANS; MYOCARDIAL REVASCULARIZATION; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

EID: 0033220524     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-199911000-00012     Document Type: Article

References (111)

1. Takeshita S, Zheng LP, Brogi E, Kearney M, Pu LQ, Bunting S, et al.: Therapeutic angiogenesis: a single intra-arterial bolus of vascular endotheliai growth factor augments revascularization in a rabbit ischemic hindlimb model. J Clin Invest 1994, 93:662-670.
2. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat Med 1995, 1:27-31.
3. Folkman J, Shing Y: Angiogenesis. J Biol Chem 1992, 267:10931-1 0934.
4. Klagsbrun M, Folkman J: Angiogenesis. In Peptide Growth Factors and Their Receptors II. Edited by Sporn MB, Robert AB, New York: Springer; 1990:549-574.
5. Weinstat-Saslow D, Steeg PS: Angiogenesis and colonization in the tumor metastatic process, basic and applied advances. FASEB J 1994, 8:401-407.
6. Montesano R: 1992 Mack Forster Award Lecture, Regulation of angiogenesis in vitro. Eur J Clin Invest 1992, 22:504-515.
7. Liotta LA, Steeg PS, Stetler-Stevenson WG: Cancer metastasis and angiogenesis, an imbalance of positive and negative regulation. Cell 1991, 64:327-336.
8. Risau W: Angiogenic growth factors. Prog Growth Factor Res 1990, 2:71-79.
9. Folkman J, Haudenschild C: Angiogenesis in vitro. Nature 1980, 288:551-556.
10. Longland CJ: The collateral circulation of the limb. Ann R Coll Surg Engl 1953, 13:161-181,
11. Piek JJ, Becker AE: Collateral blood supply to the myocardium at risk in human myocardial infarction: a quantitative post-mortem assessment. J Am Coll Cardiol 1988, 11:1 290-1 296.
12. Klagsbrun M, D'Amore PA: Regulators of angiogenesis. Annu Rev Physiol 1991, 53:217-239.
13. Chleboun JO, Martins RN, Mitchell CA, Chrilla TV: Basic FGF enhances the development of the collateral circulation after acute arterial occlusion. Biochem Biophys Res Commun 1992, 185:510-516.
14. Sellke F, Li J, Stamler A, Lopez J, Thomas K, Simons M: Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardiat ischemia. Surgery 1996, 120:1882-1888.
15. Lazarous DF, Shou M, Scheinowitz H, Hodge E, Thirumurti V, Kitsiou AN, et al.: Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury, Circulation 1996, 94:1074-1082.
16. Lazarous DF, Scheinowitz M, Shou M, Hodge E, Rajanayagam S, Hunsberger S, et al,: Effects of chronic systemic administration of basic fibroblast growth factor on collateral development in the canine heart. Circulation 1995,91:145-153.
17. Horrigan M, MacIsaac A, Nicolini F, Vince D, Lee P, Ellis S, Topol E: Reduction in myocardial infarct size by basic fibroblast growth factor after temporary coronary occlusion in a canine model. Circulation 1996, 94:1927-1933.
18. Yanagisawa-Miwa A, Uchida Y, Nakamura F, Tomaru T, Kido H, Kamijo T, et al,: Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science 1992, 257:1401-1403.
19. Harada K, Grossman W, Friedman M, Edelman E, Prasad P, Keighley C, et al.: Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts. J Clin Invest 1994, 94:623-630.
20. Unger E, Banai S, Shou M, Lazarous D, Jaklitsch M, Scheinowitz M, et al.: Basic fibroblast growth factor enhances myocardial collateral flow in a canine model. Am J Physiol 1994, 266:H1588-H1595.
21. Harada K, Friedman M, Lopez JJ, Wang SY, Li J, Prasad PV, et al.: Vascular endothelial growth factor administration in chronic myocardial ischemia. Am J Physiol 1996, 270:H1792-H1802.
22. Rosengart TK, Budenbender KT, Duenas M, Mack CA, Zhang Q-X, Isom OW: Therapeutic angiogenesis, a comparative study of the angiogenic potential of acidic fibroblast growth factor and heparin. J Vase Surg 1997, 26:302-312.
23. Banai S, Jaklitsch MT, Shou M, Lazarous DF, Scheinowitz M, Biro S, et al.: Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 1994, 89:2183-2189.
24. Asahara T, Bauters C, Zheng LP, Takeshita S, Bunting S, Ferrara N, et al,: Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 1995, 92(suppl 11):11365-11372.
25. Giordano FJ, Ping P, McKirnan MD, Nozaki S, DeMaria AN, Dillmann WH, et al.: Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med 1996, 2:534-539.
26. Losordo DW, Vale PR, Symes JF, Dunnington CH, Esakof DD, Maysky M, et al.: Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF 165 as sole therapy for myocardial ischemia. Circulation 1998, 98:2800-2804.
27. Laitinen M, Hartikainen J, Eranen J, Kiviniemi M, Hiltunen MO, Laakso M, Herttuala SY: Catheter-mediated VEGF gene transfer to human coronary arteries after angioplasty. Safety results from phase I Kuopio Angioplasty Gene Transfer Trial (KAT Trial) [abstract]. Circulation 98(suppl 1);1322.
28. Rosengart TK, Lee LY, Patel SR, Sanborn TA, Parikh M, Isom OW, et al,: Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999, 100:468-474.
29. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al.: Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275:964-967.
30. Burgess WH, Maciag T: The heparin-binding (fibroblast) growth factor family of proteins. Annu Rev Biochem 1989, 58:575-606.
31. Folkman J, Merier E, Abernathy C, Williams G: Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971, 133:275-288.
32. Gospodarowicz D, Ferrara N, Schweigerer L, Neufeld G: Structural characterization and biologic functions of fibroblast growth factor. Endocrine Rev 1987, 8:95-114.
33. Slavin J: Fibroblast growth factors: at the heart of angiogenesis. Cell Biol Int 1995, 19:431-444.
34. Baird A, Bohlen P: Fibroblast growth factors. In Peptide Growth Factors and Their Receptors. Edited by Sporn MB, Roberts AD. New York: Springer; 1990:369-418.
35. Brindle NPJ: Growth factors in endothelial regeneration. Cardiovasc Res 1993, 27:1162-1172.
36. Yayon A, Klagsbrun M, Esko J, Leder P, Ornitz D: Cell surface heparin-like molecules required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 1991, 64:841-848.
37. Moscatelli D: Metabolism of receptor-bound and matrix-bound basic fibroblast growth by bovine capillary endothelial cells. J Cell Biol 1988, 107: 753-759.
38. Brown KJ, Hondry IA, Parish CR: Acidic and basic fibroblast growth factor bind with differing affinity to the same heparan sulfate proteoglycan on BALB/c3T3 cells: implications for potentiation of growth factor action by heparin. J Cell Biochem 1995, 58:6-14.
39. Reich-Slotky R, Bonneh-Barkay D, Shaoul E, Bluma B, Svahn CM, Ron D: Differential effect of cell-associated heparan sulfates on the binding of keratinocyte growth factor (KGF) and acidic fibroblast growth factor to the KGF receptor. J Biol Chem 1994, 269:32279-32285.
40. Mason I: Cell signaling. Do adhesion molecules signal via FGF receptors? Curr Biol 1994, 4:1158-1161.
41. Schlessinger J, Lax I, Lemmon M: Regulation of growth factor activation by proteoglycans: what is the role of the low affinity receptors? Cell 1995, 83:357-360.
42. Doherty P, Smith P, Walsh FS: Shared cell adhesion molecule (CAM) homology domains point to CAMs signaling via FGF receptors. Perspect Dev Neurobiol 1995, 4:157-168.
43. Viollet C, Doherty P: CAMs and the FGF receptor: an Interacting role in axonal growth. Cell Tissue Res 1997, 290:451-455.
44. Terman B, Dougher-Vermazen M, Carrion M, Dimitrov AD, Armellino D, Gospodarowicz D, et al.: Identification of the KDR tyrosine kinase as a receptor for vascular endothelial growth factor. Biochem Biophys Res Commun 1992, 187:1579-1586.
45. Shibuya M, Yamaguchi S, Yamane A, Ikeda T ToJo A, Matsushime H, Sato M: Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (fit) closely related to the fms family. Oncogene 1990, 5:519-524.
46. Ferrara N, Henzel WJ: Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cell. Biochem Biophys Res Commun 1989, 161:851-858.
47. Gospodarowicz D, Abraham J, Schilling J: Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculostellate cells. Proc Natl Acad Sci U S A 1989, 86:7311-7315.
48. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219:983-985.
49. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT: Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989, 246:1309-1312.
50. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW: The vascular endothelial growth factor family, identification of a fourth molecule species and characterization of alternative splicing of RNA. Mol Endocrinol 1991, 5:1806-1814.
51. Leung D, Cachianes G, Kuang W-J, Goeddel D, Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246:1306-1309.
52. Ferrara N, Houck K, Jakeman L, Winer J, Leung D: The vascular endothelial growth factor family of polypeptides. J Cell Biochem 1991, 47:211-218.
53. Tischer E, Gospodarowicz D, Mitchell R, Silva M, Schilling J, Lau K, et al.: Vascular endothelial growth factor: a new member of the platelet-erived growth factor gene family. Biochem Biophys Res Commun 1989, 165: 1198-1206.
54. Olofsson B, Pajusola K, Kalpainen A, von Euler G, Joukov V, Saksela O, et al.: Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci U S A 1996, 93:2576-2581.
55. Neufeld G, Tessler S, Gitay-Goren H, Cohen T, Levi B-Z: Vascular ondothelial growth factor and its receptors. Prog Growth Factor Res 1994, 5:89-97.
56. Chilov D, Kukk E, Taira S, Jeltsch M, Kaukonen J, Palotie A, et al.: Genomic organization of human and mouse genes for vascular endothelial growth factor C. J Biol Chem 1997, 272:25176-25183.
57. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N: Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 1992, 267:26031-26037.
58. Park J, Keller G-A, Ferrara N: The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF, Mol Biol Chem 1993, 4:1317-1326.
59. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes J, Abraham J: The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991, 266:11947-11954.
60. Enholm B, Paavonen K, Ristimaki A, Kumar V, Gunji Y, Klefstrom J, et al.: Comparison of VEGF, VEGF-B, BEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene 1997, 14:2475-2483
61. Stratmann A, Risau W, Plate KH: Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 1988, 153:1459-1466.
62. Witzenbichler B, Maisonpierre PC, Jones P, Yancopoulos GD, Isner JM: Chemotactic properties of angiopoietin-1 an-2 ligands for the endothelial-specific receptor tyrosine kinase Tie2. J Biol Chem 1998, 273:18514-18521.
63. Breier G, Damen A, Plate KH, Risau W: Angiogenesis in embryos and ischemic diseases, Thromb Haemost 1997, 78:678-683.
64. Patan S: TIE1 and TIE2 receptor tyrosine kinases inversely regulate embryonic angiogenesis by the mechanism of intussusceptive microvascular growth. Microvasc Res 1998, 56:1-21.
65. Davis S, Yancopoulos GD; The angiopoietins: Yin and Yang in angiogenesis. CurrTop Microbiol Immunol 1999, 237:173-185.
66. Koblizek TI, Weiss C, Yancopoulos GD, Deutsch U, Risau W: Angiopoietin-1 induces sprouting angiogenesis in vitro. Curr Biol 1998, 8:529-532.
67. Suri C, McClain J, Thurston G, McDonald DM, Zhou H, Oldmixon EH, et al.: Increased vascularizalion in mice overexpressing angiopoietin-1. Science 1998, 282:468-471.
68. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, et al.: Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997, 277:55-60.
69. Asahara T, Chen D, Takahashi T, Fujikawa K, Kearney M, Magner M, et al,: Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res 1998, 83:233-240.
70. Takeshita S, Yukio T, Thierry C, Takayuki A, Bauters C, Symes J, et al.: Gene transfer of naked DNA encoding for three isoforms of vascular endothelial growth factor stimulates collateral development in vivo. Lab Invest 1996, 75:487-501.
71. Baumgartner I, Magner M, Pieczek AM, Isner JM; Clinical evidence that vascular endothelial growth factor enhances vascular permeability [abstract]. Circulation 1997, 96:1491.
72. Magovern CJ, Mack CA, Zhang J, Rosengart TK, Isom OW, Crystal RG: Regional angiogenesis induced in non-ischemic tissue by an adenoviral vector expressing vascular endothelial growth factor. Hum Gene Ther 1997, 9:215-227.
73. Isner JM, Pieczek A, Schainfeld R, Blair R, Haley L, Asahara T, et al.: Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischemic limb. Lancet 1996, 348:370-374.
74. Mack CA, Patel SR, Schwarz EA, Zanjonico P, Hahn RT, Ilercil A, et al.: Biological bypass utilizing adenovirus-mediated gene transfer of the cDNA for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J Thorac Cardiovasc Surg 1998, 115:167-177.
75. Mack CA, Magovern CJ, Budenbender KT, Patel SR, Schwarz EA, Zanzonico P, et al.: Salvage angiogenesis induced by adenoviral-mediated gene transfer of vascular endothelial growth factor protects against ischémie vascular occlusion. J Vasc Surg 1998, 27:699-709.
76. Magovern CJ, Mack CA, Zhang J, Rosengart TK, Isom OW, Crystal RG: Regional angiogenesis induced in non-ischemic tissue by an adenoviral vector expressing vascular endothelial growth factor. Hum Gene Ther 1997, 8:215-227.
77. Magovern CJ, Mack CA, Zhang J, Hahn RT, Ko W, Isom OW, et al.: Direct in vivo gene transfer to canine myocardium using a replication-deficient adenovirus vector. Ann Thorac Surg 1996, 62:425-434.
78. Rakhmilevich AL, Janssen K, Turner J, Culp J, Yanf NS: Cytokine gene therapy of cancer using gene gun technology: superior antitumor activity of interleukin-12. Hum Gene Ther 1997, 8:1303-1311.
79. Pinnaduwage P, Schmitt L, Huang L: Use of a quaternary ammonium detergent in liposome mediated DNA transfection of mouse L-cells, Biochem Biophys Acta 1989, 985:33-37.
80. Reimer DL, Zhang Y, Kong S, Wheeler JJ, Graham RW, Bally MB; Formation of novel hydrophobia complexes between cationic lipids and plasmid DNA. Biochemistry 1995, 34:12877-12883.
81. Mack CA, Magovern CJ, Budenbender KT, Patel SR, Schwarz EA, Zanzonico P, et al.: Salvage angiogenesis Induced by adenoviral-mediated gene transfer of vascular endothelial growth factor protects against ischémie vascular occlusion. J Vase Surg 1998, 27:699-709.
82. Lin H, Parmacek MS, Morie G, Boiling S, Leiden JM: Expression of recombinarit genes in myocardium in vivo after direct injection of DNA. Circulation 1990, 83:2217-2221.
83. Stewart MJ, Plautz GE, Del Buono L, Yang ZY, Xu L, Gao X, et al.: Gene transfer in vivo with DNA-liposome complexes, safety and acute toxicity in mice. Hum Gene Ther 1992, 3:267-275.
84. Crystal RG: Transfer of genes to humans: early lessons and obstacles to success. Science 1995, 270:404-410.
85. Horwitz MS: Adenoviridao and their replication. In Virology. Edited by Fields BN, Knipe DM, Howley PM, Chanock RM Melnick JL, Monath TP, et al. New York: Raven; 1990:1679-1740.
86. Crystal RG, McElvaney NG, Rosenfeld MA, Chu CS, Mastrangeli A, Hay JG, et al.: Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet 1994, 8:42-51.
87. Nabel EG, Pompili VJ, Plautz GE, Nabel GJ: Gene transfer and vascular disease. Cardiovasc Res 1994, 28:445-455.
88. Zabner J, Petersen DM, Puga AP, Graham SM, Couture LA, Keyes D, et al.: Safety and efficacy of repetitive adenovirus-mediated transfer of CFTR cDNA to airway epithelia of primates and cotton rats. Nat Genet 1994, 6:75-83.
89. Rosenfeld MA, Yoshimura K, Trapnell BC, Yoneyama K, Rosenthal ER, Dalemans W, et al.: In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to airway epithelium. Cell 1992, 68:143-155.
90. Yang Y, Nunes FA, Bemcsi K, Furth EE, Gonczol E, Wilson JM: Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994, 91:4407-4411.
91. Yang Y, Joos KU, Su Q, Ertl HCJ, Wilson JM: Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther 1996, 3:137-144.
92. Yang Y, Li Q, Ertl HCJ, Wilson JM: Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995, 69:2004-2015.
93. Crystal RG, Rosengart TK, Isom OW, Devereux RB, Sanborn TA, Zanzonico P, et al.: Phase I study of direct administration of a replication deficient adenovirus vector (AdGVVEGF121.10) containing the VEGF121cDNA to the ischemic myocardium of individuals with life threatening diffuse coronary artery disease. RAC Report #9711-221, Bethesda, MD: National Institutes of Health; 1997. Available from Office of Recombinant DNA Activities, National Institutes of Health, Suite 323, 6006 Executive Boulevard, MSC 7052, Bethesda, MD 20892-7052, USA.
94. Cone RD, Mulligan RC: High-efficiency gene transfer into mammalian cells: generation of helper-free recombinant retrovirus with broad mammalian host gene. Proc Natl Acad Sci U S A 1984, 81:6349-6353.
95. Lebkowski JS, McNally MM, Okarma TB, Lerch LB: Adeno-ssociated virus: a vector system for efficient introduction and integration of DNA into a variety of mammalian cell types, Mol Cell Biol 1988, 8:3988-3996.
96. Kotin RM, Sininscalco M, Samulski RJ, Zhu XD, Hunter L, Laughlin CA, et al.: Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA 1990, 87:2211-2215.
97. Berns KI, Kotin RM, Labow MA: Regulation of adeno-associated virus DNA replication. Biochem Biophys Acta 1988, 951:425-429.
98. Kaplitt MQ, Xiao X, Samulski RJ, Li J, Ojamaa K, Klein IL, et al.: Long-term gene transfer in porcine myocardium after coronary infusion of an adeno-associated virus vector, Ann Thorac Surg 1996, 62:1669-1676.
99. Samulski RJ, Chang LS, Shenk T: A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication. J Virol 1987, 61:3096-3101.
100. Samulski RJ, Chang LS, Shenk T: Helper-free stocks of adeno-associated viruses: normal integration does not require viral gene expression. J Virol 1989, 63:3822-3828.
101. Rowland RT, Cleveland JC, Meng X, Harken A, Brown JM: Potential gene therapy strategies in the treatment of cardiovascular disease. Ann Thorac Surg 1995, 60:721-728.
102. Grossman M, Raper S, Wilson J: Transplantation of genetically modified autologous hepatocytes into nonhuman primates: feasibility and short-term toxicity. Hum Gene Ther 1992, 3:501-510.
103. Grossman M, Rader D, Muller D, Kolansky D, Kozarsky K, Clark BJ 3d, et al.: A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolemia. Nat Med 1995, 11:1148-1154.
104. Malosky S, Kolansky DM: Gene therapy for ischemic heart disease. Curr Opin Cardiol 1996, 11:361-368.
105. Chowdhury JR, Grossman M, Gupta S, Chowdhury R, Baker JR, Wilson JM: Long-term improvement of hypercholesterolemia after ex vivo gene therapy in LDLR-deficient rabbits. Science 1991, 254:1802-1809.
106. Smith LC, Eisensmith RC, Woo LC: Gene therapy in heart disease. Adv Exp Med Biol 1995, 369:79-88.
107. Schurnacher B, Pecher P, von Specht BU, Stegmann T: Induction ot neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation 1998, 97:645-650.
108. Schumacher B, Stegmann T, Pecher P: The stimulation of new angiogenesis in the ischemic human heart by the growth factor FGF: first clinical results. J Cardiovasc Surg 1998, 39:783-789.
109. Sellke FW, Laham RJ, Edelman ER, Pearlman JD, Simons M: Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results. Ann Thorac Surg 1998, 65:1 540-1544.
110. Thirumurti V, Shou M, Hodge E, Goncalves L, Epstein SE, Lazarous DF, Unger EF: Lack of efficacy of intravenous basic fibroblast growth factor in promoting myocardial angiogenesis [abstract]. J Am Coll Cardiol 1998, 2(suppl A):54A.
111. Henry TD, Rocha-Singh K, Isner JM, Kerciakes DJ, Giordano FJ, Simons M, et al.: Results of intracoronary recombinant human vascular endothelial growth factor (rhVEGF) administration trial [abstract]. J Am Coll Cardiol 1993, 2(suppl A):65A.